Effect of Mosapride on Gut Transit in Patients With Chronic Constipation or Constipated Irritable Bowel Syndrome and Healthy Subjects

Status

UNKNOWN

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02433847

Enrollment

Registered

2015-05-05

Start date

2015-05-31

Completion date

2016-12-31

Last updated

2015-05-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Constipation, Constipated Irritable Bowel Syndrome, Healthy

Keywords

mosapride

Brief summary

Effect of mosapride 30mg/day on the small bowel and colon transit time in patients with chronic constipation or constipated irritable bowel syndrome.

Interventions

DRUGMosapride

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

19 Years to No maximum

Healthy volunteers

Inclusion criteria

* Functional constipation or constipated irritable bowel syndrome patients according to Rome III criteria

Exclusion criteria

* Intolerable or hypersensitive to mosapride * Known Parkinson's ds * Cardio- or cerebrovascular disease within 3 months * Malignancy requiring surgery or chemotherapy or radiation within 5 years * History of GI surgeries except hernia repair, appendectomy, primary closure due to perforation * Refractory diabetes mellitus/hypertension/thyroid diseases * Symptomatic heart failure, renal failure, arrhythmia

Design outcomes

Primary

Measure	Time frame	Description
colonic transit time	2 weeks	the change of colonic transit time after mosapride 30mg/day administration : whole colonic transit time, rt. colon / lt. colon / rectosigmoid colonic transit time

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026